A5035036126- Inflammatory Bowel Disease
- Gut microbiota and health
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Microscopic Colitis
- Gastrointestinal motility and disorders
- Barrier Structure and Function Studies
- CAR-T cell therapy research
- Mycobacterium research and diagnosis
- Immune Cell Function and Interaction
- Pharmacological Effects of Natural Compounds
- Herpesvirus Infections and Treatments
- Renal cell carcinoma treatment
- Drug Transport and Resistance Mechanisms
- Gastrointestinal Tumor Research and Treatment
- Digestive system and related health
- Cytomegalovirus and herpesvirus research
- Diet and metabolism studies
- Bone health and treatments
- Liver Disease Diagnosis and Treatment
- Renal and related cancers
- Epigenetics and DNA Methylation
- Autoimmune and Inflammatory Disorders
- Gastrointestinal disorders and treatments
- Radiopharmaceutical Chemistry and Applications
Immunicum (Sweden)
2018-2022
GlaxoSmithKline (Belgium)
2013
Amgen (United States)
2011
KU Leuven
2003-2011
Montreal General Hospital
2005
McGill University Health Centre
2005
Universitair Ziekenhuis Leuven
2000
A primary defect of the tight junctions and, hence, increased intestinal epithelial permeability has been proposed as a basic pathogenic event in Crohn's disease. Challenge mucosal immune system by commensal gut flora would then result chronic inflammation. Alternatively, could be Our aim was to study refractory disease before and after treatment with monoclonal chimeric antibodies directed against tumor necrosis factor (TNF) investigate whether abnormal persists control...
Gut – brain communications disorders in irritable bowel syndrome (IBS) are associated with intestinal microbiota composition, increased gut permeability, and psychosocial disturbances. Symptoms of IBS difficult to medicate, hence much research is being made into alternative approaches. This study assesses the potential a treatment pasteurized Akkermansia muciniphila for alleviating IBS-like symptoms two mouse models different etiologies. Two clinically relevant animal were used mimic...
The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy children adolescents. As inhibitors, both as monotherapy combinations have shown impressive success some adult malignancies early phase trials of single agent now been completed, it seemed an appropriate time to consider opportunities paediatric studies used combination. Among patients, clinical demonstrated a...
Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe renal-cell carcinoma. Here, we assessed as a single agent and combined with sorafenib advanced HCC. Of 17 HCC patients enrolled, 12 received at dose 10 × 106 cells (six monotherapy six combination sorafenib), five 20 monotherapy. The primary objective was to evaluate tolerability. All...
Background The spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent, affecting 30% the world’s population, with a significant risk hepatic and cardiometabolic complications. Different stages MASLD are accompanied by distinct gut microbial profiles, several components have been implicated in pathophysiology. Indeed, earlier studies demonstrated that necroinflammation was reduced individuals after allogenic faecal microbiota transplantation (FMT)...
Aliment Pharmacol Ther 2011; 34: 526–532 Summary Background Butyrate, a colonic metabolite of carbohydrates, is considered as the major energy source for mucosa. An impaired butyrate metabolism has been reported in ulcerative colitis (UC), however, cause still remains unknown. Aim In present study, we investigated whether higher concentrations could normalise oxidation rate UC. Furthermore, it was carnitine enhance oxidation. Methods Mucosal biopsies from total 26 UC patients and 25 controls...
Healthy colonic mucosa uses butyrate as the major energy source. In ulcerative colitis (UC) oxidation has been shown to be disturbed, but it remains unclear whether this is a primary defect. The aim of study was measure mucosal in UC (involved and noninvolved colon) pouchitis relationship with endoscopic well histological disease activity.Butyrate measured 73 patients, 22 112 controls (95 colon, 17 ileum) by incubating biopsies 1 mM 14C-labeled Na-butyrate measuring released 14CO2.Compared...
Abstract Background The majority of patients with advanced gastrointestinal stromal tumor (GIST) develop resistance to imatinib, and subsequent treatments have limited efficacy. Ilixadencel (allogeneic inflammatory dendritic cells) is a cell-based immune primer injected intratumorally that previously has been clinically investigated in metastatic renal cell carcinoma hepatocellular carcinoma. Methods trial was single arm phase I assessing safety efficacy ilixadencel subjects progressing...
Crohn's disease (CD) is associated with gut barrier dysfunction. Besides the baseline defect, a subgroup of patients also expresses an intestinal hyperresponsiveness to nonsteroidal anti-inflammatory drugs. We studied whether reducing inflammation and restoring dysfunction anti-tumor necrosis factor (TNF) antibody treatment antagonizes permeability increase by oral drug intake in CD.Thirty-one healthy control subjects 25 active CD were studied. The 31 controls performed testing for Cr-EDTA...
Epithelial barrier disturbance is thought to contribute the pathogenesis of inflammatory bowel diseases; however, it remains unclear whether a primary defect participating onset inflammation or only consequence sustained inflammation.A time course study epithelial functions and immune mediators was performed in CD4(+)CD45RB(hi) T cell transfer model colitis using Ussing chambers.In nonreconstituted severe combined immunodeficiency (SCID) mice, no dysfunction observed. However, after cells...
The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) clearly insufficient, the effects can be enhanced by combinations immune checkpoint inhibitors. Innovative treatment options combining TKI and other immune-stimulating agents could prove beneficial.To evaluate clinical on disease when two doses allogeneic monocyte-derived dendritic cells (ilixadencel) are administrated intratumorally followed...
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted immune-based treatments for melanoma. After decades unsuccessful attempts to finding more effective cure in treatment melanoma now we several drugs active The possibility use these combination improve responses overcome resistance, potentiate action immune system with immunomodulating antibodies, identification biomarkers that can predict response particular therapy represent...
Intratumoral administration of an immune primer is a therapeutic vaccine strategy aimed to trigger dendritic cell (DC)-mediated cross-presentation cell-associated tumor antigens cytotoxic CD8+ T cells without the need for antigen characterization. The prevailing view that these cross-presenting DCs have be directly activated by pathogen-associated molecular patterns (PAMPS), including Toll-like receptor ligands or live microbial agents like oncolytic viruses. Emerging data are however...
Background: Smoking reduces the non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal permeability increase in healthy people. It also affects inflammatory bowel disease that is associated with a disturbed gut barrier function. To assess role of nicotine on function, its influence basal and NSAID-induced was studied volunteers. Methods: Thirty-one non-smoker subjects performed tests 51Cr-EDTA sugar markers (sucrose, lactulose, mannitol, sucralose) before during 2 weeks patch...
11 Background: Ilixadencel is a cell-based allogeneic off-the-shelf product aimed to prime anti-cancer immune response when injected intratumorally. The present randomized Phase II multicenter trial (MERECA; NCT02432846) evaluated intratumoral ilixadencel administration (2 doses 2 weeks apart) pre-nephrectomy followed by sunitinib post-nephrectomy compared with monotherapy as first-line systemic therapy in patients newly diagnosed synchronous metastatic renal cell carcinoma (mRCC). Methods:...
We describe a case of systemic cytomegalovirus (CMV) infection in an ulcerative colitis patient admitted to the hospital for acute flare-up his colitis. He was treated with combination immunosuppresive therapy including IV cyclosporine and corticosteroids PO azathioprine. Severe bilateral stabbing knee pain only manifestation CMV disease, which quickly responded adequate antiviral therapy.
15 Background: Ilixadencel is a cell-based, off-the-shelf product based on allogeneic monocyte-derived inflammatory cells aimed to prime an anti-cancer immune response when injected intratumorally. The present single arm Phase I trial (ClinicalTrials.gov Identifier: NCT02686944) assessed the safety and efficacy of ilixadencel in subjects with progressing advanced/metastatic GIST despite ongoing treatment second or later lines tyrosine kinase inhibitors (TKI). Methods: Three patients were...
We describe a case of systemic cytomegalovirus (CMV) infection in an ulcerative colitis patient admitted to the hospital for acute flare-up his colitis. He was treated with combination immunosuppresive therapy including IV cyclosporine and corticosteroids PO azathioprine. Severe bilateral stabbing knee pain only manifestation CMV disease, which quickly responded adequate antiviral therapy.